Novo Nordisk’s CagriSema Delivers Superior Diabetes Control
PLAINSBORO, New Jersey and BAGSVÆRD, Denmark, June 7, 2026 Novo Nordisk has reported compelling Phase 3 results demonstrating that...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PLAINSBORO, New Jersey and BAGSVÆRD, Denmark, June 7, 2026 Novo Nordisk has reported compelling Phase 3 results demonstrating that...
VANCOUVER, British Columbia, June 2, 2026 Clarius Mobile Health has achieved a significant regulatory milestone with the U.S. Food...
